NEW YORK, July 31, 2026, 10:59 a.m. EDT — U.S. markets are now open.
- The stock climbed 173.5% to $0.8029 as of 10:43 a.m. EDT.
- Nuclea shareholders are set to hold 96%, while current Mango investors keep 4% prior to the PIPE.
- The deal closing is contingent on securing a minimum of $15 million in PIPE financing.
Mangoceuticals shares surged almost threefold on Friday morning following the announcement of a nuclear reverse merger. The stock traded at $0.8029, marking a 173.5% increase from the previous day’s close, after touching a high of $1.23 earlier. Trading volume surpassed 350.5 million shares.
Turnover serves as a more telling indicator. According to the filing, 9.12 million support shares represent nearly 50.1% of the existing stock. This suggests there are approximately 18.2 million shares in total. Based on that initial assessment, Friday’s trading volume amounted to 19.3 times the number of shares outstanding.
| Friday tape | 10:43 a.m. EDT | Baseline | Change or multiple |
|---|---|---|---|
| Share price | $0.8029 | $0.2936 last close | up 173.5% |
| Intraday high | $1.23 | $0.2936 last close | up 318.9% |
| Trading volume | 350.5 million | Roughly 18.2 million shares | 19.3-fold |
Market data reflect a delay. Share counts are based on early calculations.
The agreement pivots the focus from telehealth to next-generation nuclear technology. Mango has entered into a merger with Nuclea Energy, a private reactor developer. Previous Nuclea shareholders will take 96% of the fully diluted equity, while current Mango stakeholders will keep 4%, prior to PIPE share issuance.
The exchange ratio applies a factor of 24. Any rights exceeding 19.99% remain deferred, pending approval from shareholders and Nasdaq. Finalization of the deal also depends on securing a minimum of $15 million in PIPE funding. No valuation amount for Nuclea was disclosed in the provided materials.
| Deal item | Stated term | Investor consequence |
|---|---|---|
| Nuclea holders | Roughly 96% pre-PIPE | Majority control post-close |
| Current Mango holders | Approximately 4% pre-PIPE | Minority stake |
| Exchange factor | 24x | Significant issuance allocated to Nuclea |
| PIPE financing | Minimum $15 million | Future dilution linked to final valuation |
| Interim Nasdaq cap | 19.99% | Rights above cap are postponed |
Ownership shares are fully diluted and as-exchanged, prior to PIPE being issued.
Initial valuation calculations underscore the gap. Using Friday’s $13.2 million market cap and dividing by the 4% ownership yields roughly $331 million. This represents a mechanical pro-forma number rather than the transaction value. It does not factor in PIPE dilution and presumes Friday’s share price holds through closing.
Morpheus is still in the conceptual design phase. Nuclea reports that output may vary between 3.5 and 50 megawatts-electric. The firm has also outlined an 18-month development plan. Chief Executive Josef Freundorfer stated a listing should provide “capital access and visibility.” SEC
Other listed nuclear companies maintain significantly greater market capitalisations. Oklo Inc. NYSE:OKLO had a market value of $6.69 billion. NuScale Power Corp. NYSE:SMR traded at nearly $2.70 billion. Nano Nuclear Energy Inc. NASDAQ:NNE was valued at approximately $824 million.
| Nuclear-market scale | Market value | Friday move | Versus $331 million estimate |
|---|---|---|---|
| Mango live capitalization | $13.2 million | up 173.5% | 0.04 times |
| Mechanical combined estimate | $330.8 million | not applicable | 1.0 time |
| Nano Nuclear Energy | $824.3 million | down 4.3% | 2.5 times |
| NuScale Power | $2.70 billion | down 1.7% | 8.2 times |
| Oklo | $6.69 billion | down 4.4% | 20.2 times |
The mechanical estimate does not represent a revealed transaction value.
The comparison illustrates scale rather than technical parity. Nuclea’s filing refers to Morpheus as a concept. The disclosed 8-K excluded audited Nuclea figures. Investors continue to lack conventional reference points for revenue, cash, or backlog.
Legacy Mango reported a 38% decline in first-quarter revenue, down to $67,864. The net loss tightened by 30%, reaching $3.40 million. Cash holdings dropped to $174,562 as of March 31.
| Legacy business | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $67,864 | $109,306 | -37.9% |
| Gross profit | $29,001 | $62,064 | -53.3% |
| Net loss | $3.40 million | $4.84 million | Loss dropped 29.7% |
| Stock compensation | $1.65 million | $1.05 million | up 57.6% |
Numbers reflect unaudited results for the quarter.
The minimum PIPE is roughly 86 times Mango’s cash on hand in March. This highlights that access to capital is a key factor in the deal. It also means that the value of the financing is crucial to the current valuation.
Following the closing, management roles will shift. Freundorfer will take over as chief executive, while Sagar Sanghera is slated to be appointed executive chairman. Mango’s current CEO, Jacob Cohen, will transition to president in a consulting capacity.
Risks: Morpheus remains in the conceptual stage and must obtain nuclear licenses. The deal is subject to consent from shareholders, Nasdaq, and regulators. Mango is also seeking an additional bid-price grace period ahead of August 3. Terms of the PIPE could create extra dilution for current shareholders.
The tape indicates that traders are prioritising the nuclear strategy over Mango’s health division sales. Upcoming key hurdles include Nuclea’s financial disclosures, the PIPE valuation, and Nasdaq’s approval.
Related articles: Pharmaceuticals
